Frontiers in Pharmacology (Aug 2022)
Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data
Abstract
No abstracts available.Keywords